Wells Fargo’s Context Therapeutics CNTX Stock Holding History

Wells Fargo’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.1K	Buy	+84,981	New	+$172K	﹤0.01%	5730
2024 Q2	–	Sell	-116	Closed	-$160	–	6993
2024 Q1	$160	Buy	116 +2	+2%	+$2	﹤0.01%	6547
2023 Q4	$129	Buy	114 +6	+6%	+$6	﹤0.01%	6706
2023 Q3	$163	Buy	108 +1	+0.9%	+$1	﹤0.01%	6634
2023 Q2	$171	Buy	107 +4	+4%	+$3	﹤0.01%	6744
2023 Q1	$58	Buy	103 +2	+2%	+$2	﹤0.01%	7068
2022 Q4	$66	Buy	101 +2	+2%	+$2	﹤0.01%	6916
2022 Q3	$0	Buy	99 +30	+43%	+$54	﹤0.01%	6733
2022 Q2	$0	Buy	69 +5	+8%	+$9	﹤0.01%	6873
2022 Q1	$0	Buy	64 +31	+94%	+$65	﹤0.01%	7138
2021 Q4	$0	Buy	+33	New	+$165	﹤0.01%	7275

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wells Fargo's CNTX Position: Q2 2026 in Review

Wells Fargo opened a new position in Context Therapeutics (CNTX) in Q2 2026: 84,981 shares worth $47.1K. The stake represents ﹤0.01% of the portfolio and ranks #5730 among its holdings. This is a return to the name: Wells Fargo previously reported a position in CNTX as recently as Q1 2024.

Wells Fargo first reported a position in CNTX in Q4 2021 and has held it in 11 quarters since. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Wells Fargo held 84,981 shares of Context Therapeutics worth $47.1K as of Q2 2026.
Context Therapeutics was a new Wells Fargo position in Q2 2026.
Context Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5730 holding.
Wells Fargo first reported a position in Context Therapeutics in Q4 2021 and has held it in 11 quarters since.
79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.